Advertisement
Advertisement

GMAB

GMAB logo

Genmab A/S ADS

28.61
USD
-0.07
-0.23%
Oct 31, 16:00 UTC -4
Closed
exchange

After-Market

28.61

0.00
0.00%

Genmab A/S ADS Profile

About

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.

Info & Links

CEO

Jan G. van de Winkel

Headquarters

CARL JACOBSENS VEJ 30
VALBY, G7 2500, DENMARK

Sector

Medical

Auditor

Deloitte Statsautoriseret Revisionspartnerselskab

Share holders

--

Employees

2,682

Genmab A/S ADS Statistics

Valuation Measures

Market Capitalization2

17.61B

Enterprise Value

16.31B

Enterprise Value/EBITDA(ttm)

13.23

Price to Earnings Ratio(ttm)

16.93

Price to Sales(ttm)

5.50

Price to Book(mrq)

3.50

Price to Cash(ytd)

19.09

Profitability

Gross Margin(ttm)

94.47%

Operating Margin(ttm)

32.11%

Profit Margin(ttm)

36.67%

Return on Equity(ttm)

21.03%

Return on Invested Capital(ttm)

24.80%

Return on Assets(ttm)

16.98%

Income Statement

Revenue(ttm)

3.38B

Revenue Per Share(ttm)

--

Gross Profit(ttm)

3.19B

EBITDA(ttm)3

1.23B

Net Income Available to Common(ttm)

1.27B

Diluted EPS(ttm)

1.99

Share Statistics

Beta (5Y Monthly)

0.98

52-Week Change

26.74%

S&P 500 52-Week Change

19.40%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

0.00%

Float4

632.17M

% Held by Insiders

1.54%

% Held by Institutions

7.07%

Balance Sheet

Total Cash(mrq)

2.90B

Total Cash Per Share(mrq)

--

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.22%

Quick Ratio(mrq)

6.20%

Book Value Per Share(mrq)

8.26

Cash Flow

Operating Cash Flow Per Share(ytd)

0.56

Free Cash Flow(ytd)

327.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement